Background and aims: The aim was to derive health state utility scores in ulcerative colitis (UC) by establishing the relationship between the physician-rated ulcerative colitis disease activity index (UCDAI) and a patient reported EQ-5D by statistically mapping the two instruments. Methods: In a randomised controlled trial comparing oral plus enema mesalazine treatment with oral mesalazine treatment alone (PINCE), UCDAI and EQ-5D scores were collected in parallel from patients with active UC. From these data, multinomial logistic regression was used to estimate response probabilities to each of the five domains of the EQ-5D index from assessment of UC disease severity using original and abbreviated (no endoscopy) versions of the UCDAI. Predicted EQ-5D responses were converted by Monte Carlo simulation to the EQ-5D index for predicting health-related quality of life (HRQoL). The reliability of the algorithm was tested using UCDAI scores from a second mesalazine RCT (PODIUM). Results: The abbreviated-UCDAI showed comparable explanatory performance to the full UCDAI. For patients in remission, mean utility was 0.939, 0.944, and 0.940 U for PINCE estimated , PINCE observed , and PODIUM, respectively. Mild/moderate and relapsing cases showed mean utilities of 0.801, 0.811, and 0.775, respectively; whilst for those in severe relapse, the mean utilities were 0.630, 0.700 and 0.660 units, respectively. The mean squared error between actual and predicted utilities from observations in PINCE was 0.019. Conclusion: Response mapping of UC activity to EQ-5D domains produced reliable estimates of patient-rated health state utility consistent with UCDAI rated severity. and full UCDAI suggests that inclusion of endoscopy scores has limited predictive value in estimating patient HRQoL.
Introduction
Increasingly, there is a need to assess costs in relation to benefits often using a cost-effectiveness analysis in all areas of healthcare, and ulcerative colitis (UC) treatments are no exception. Even for widely used and accepted treatments such as mesalazine routine used for treating ulcerative colitis (UC), there is often the need to evaluate the cost-effectiveness of changes in medical practices that can evolve over time. 1, 2 To aid healthcare priority-setting and decision-making national technology appraisal agencies prefer that common, meaning similar outcome measures are used in a costeffectiveness analysis so that outcomes can be compared across different health conditions. 3 Obtaining common outcome measures require that clinical studies include generic health-related quality of life instruments (HRQoL). 4 Methods for measuring health state utility vary, however the common feature is that health states are rated using a single index in which 1.0 represents perfect health and zero represents death. When the health state utility value is combined with time spent in a particular health (disease) state, the qualityadjusted life year (QALY) is determined. Because QALYs include morbidity and mortality in a single measure they have increasingly become the preferred outcome for comparing health conditions and priority-setting. 3 Symptoms of UC are known to impact upon quality of life (QoL) and influence psychological and social functioning as well as cause distress for patients because of uncertainty about losing bowel control, and possibly developing colon cancer. 5, 6 Despite the understanding that UC has a considerable impact on QoL, the impact of the condition on health state utility has not been well characterised and often precludes deriving QALYs directly measured in clinical trials for conducting a costeffectiveness analysis. Recent drug reimbursement appraisals have called for research on the utility of different health states in gastroenterology and how these relate to existing measurement scales. 7 The generic instrument preferred by the National Institute for Health and Clinical Excellence for eliciting utility values for health states is the EQ-5D. 8 Clinical trials in UC seldom include HRQoL measures for deriving utility associated with different levels of disease severity necessary for conducting a cost-effectiveness analysis. 9 This shortage of information can be overcome in situations where disease specific data, for example the ulcerative colitis disease activity index (UCDAI), and HRQoL measures are collected simultaneously in clinical trials using statistical modelling. 10 This process is commonly termed 'mapping' and enables investigators to use scores from one instrument to derive related values on a different instrument.
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For evaluating UC disease activity numerous indices have been developed using a range of clinical, biomedical, and endoscopic evaluations, none of which have been validated. 9 Recent studies have also questioned the contribution of endoscopy for measuring UC disease activity. 12 The lack of standardisation and agreement on which outcomes to include for measuring disease activity makes it difficult to compare results and may impair the registration or adoption of new treatments, as well as increasing the potential for exposing patients to diagnostics that add limited information to informed clinical decisions. 13 With the above points in mind, there were two aims of this study. Firstly, to derive health state utility values for UC severity categories by statistically mapping the UCDAI to the EQ-5D
14 using data from a randomised controlled clinical trial. The purpose of this exercise was to reliably estimate utility in recognised UC disease states that could be used to derive QALYs for use in economic studies. Secondly, in the spirit of the study reported by Higgins et al. we sought to understand the contribution of endoscopy scores collected as part of the UCDAI instrument for predicting patient reported utility as measured using the EQ-5D. 12 This was achieved by mapping scores to individual items of the UCDAI to the patient reported EQ-5D using both the original four-item UCDAI and the abbreviated version of the UCDAI that excludes endoscopy scores.
Methods

Data sources
Data for this study were derived from two randomised clinical trials (RCTs). Both of the studies described in this analysis and previously reported by Marteau et al. and Dignass et al. were reviewed by an Independent Ethics Committee (IEC) or Institutional Review Board (IRB). 15, 16 The IEC/IRB reviewed the patient information sheet and the informed consent form, updates, and any written material given to the patients. The study was conducted in accordance with the ethical principles that have their origins in the 'Declaration of Helsinki'.
Response mapping and internal validation was carried out using data from the Phase IV PINCE study (combined oral and enema treatment with mesalazine in patients with extensive active ulcerative colitis). 15 In this RCT, 127 ambulatory patients received oral mesalazine for 8 weeks. During the initial four week period they also received an enema at bedtime containing either 1 g of mesalazine or a placebo.
Disease activity was assessed using the UCDAI at baseline, 4 and 8 weeks. The UCDAI is a four-item disease activity index assessing (1) stool frequency, (2) rectal bleeding, (3) endoscopic evaluation of mucosa and (4) physician global assessment (PGA) and each item is scored for severity as shown in Table 1 . 10 At week two the UCDAI was completed without endoscopic evaluation based on clinical signs and symptoms (i.e. abbreviated-UCDAI). UC disease severity was classified according to the sum score with the UCDAI as follows: sum score 0-2 (none or light [remission]); 3-8 (mild-to-moderate relapse); and 9-12 (severe relapse).
Estimates of patient HRQoL for deriving health state utility scores were evaluated using the EQ-5D at baseline, 2, 4 and 8 weeks.
14 The EQ-5D assesses five dimensions of health as follows: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. For each dimension there are three response categories described as (1) no problem; (2) some problems; and (3) extreme problems. Based on the five health dimensions evaluated and three response categories there are 243 unique health states. The mapping exercise in this study will map UC severity categories of remission, mildto-moderate and severe to establish their EQ-5D index.
The usefulness of the algorithm to discriminate the differential utility using the EQ-5D amongst UC patients with varying disease severities was tested using data from the Phase IV PODIUM study (pentasa once daily in ulcerative colitis for maintenance of remission). 16 In this 12-month, multicentre investigator-blinded RCT, patients with mild-to-moderate UC in remission with a relapse within the past year were randomised to receive either mesalazine granules 2 g per day given once daily (OD) or twice daily (BD). Clinical evaluations using the UCDAI were undertaken at baseline, 4, 8 and 12 months.
Statistical methods
Response mapping was used to predict the likely response to a multi-level question from known responses to different instrument/set of questions. 17 Response mapping employs a form of polynomial logistic regression to calculate the probability of each possible response to a question. Two techniques are available: (1) a standard ordered logit model, where polychotomous responses are assumed to be ordinal in nature and (2) multinomial logistic regression where no inherent value is assumed across the range of responses. The ordered logit model relies on an assumption of proportional odds whereby the cumulative probability curves for the different ordered categories have parallel slopes. Multinomial regression does not rely on this assumption and maintains statistical power. 17 In this study multinomial regression models were constructed to predict responses for each of the five EQ-5D domains from both UCDAI and abbreviated-UCDAI item assessments. Models were developed using forward stepwise iteration. The probability for parameter inclusion in the model was 0.05 and for removal probability was set at 0.1, each based on the likelihood ratio test for model fit. Models were tested that used either UCDAI item scores or the summary disease activity score. For each EQ-5D domain the efficacy of the full UCDAI or the abbreviated-UCDAI model was compared using the Nagelkerke pseudo-R 2 value for predicting the EQ-5D index where values of 1.0 suggests the regression perfectly fits the data. 18 The parameter estimates for each of the EQ-5D domain response regression models were applied in separate Excel spreadsheets using the Monte Carlo simulation method developed by Gray et al. as follows. 17 Firstly, the log-odds obtained from the regressions were used to derive the probability that a respondent would select response level 1, 2, or 3 on each dimension of the EQ-5D given their observed UCDAI responses. Secondly, the probabilities derived at step 1 were then compared against random numbers. Specifically, to achieve a predicted EQ-5D health state other than 1 (i.e. no problem in that dimension) the predicted probability for the health state must exceed the random number. This procedure, rather than taking the most likely predicted value, is necessary to ensure that unbiased expected values are obtained. Lastly, having obtained a predicted health state on the EQ-5D, the appropriate tariff was applied to estimate health-related utility.
Goodness of fit was determined via calculation of the mean square error (MSE) for mean predicted utility scores and by the proportion of predictions lying within 0.03 and 0.1 utility units 1 of the actual EQ-5D index. 19 Sample size in regressionbased studies mapping descriptive measures of health states to utility values varies enormously from a few tens to many thousands. 11 As each of the 127 PINCE study participants completed at least three EQ-5D surveys (at baseline, 4 weeks and 8 weeks) we felt that empirically mapping the two instruments was feasible. There were few cases with missing data and these were excluded from the analysis.
Results
There were 326 evaluable responses in the PINCE dataset with full UCDAI assessments (including endoscopic examination) matched to completed EQ-5D questionnaires from 126 individual patients. For abbreviated-UCDAI (without endoscopic assessment) there were 441 responses with completed EQ-5D data based on abbreviated-UCDAI data collected at week-2 plus full UCDAI index evaluations collected at baseline, week-4, and week-8 with endoscopy scores removed. Fifty-nine percent of Table 2 ). The majority of cases (92%) were in mild-to-moderate relapse at baseline, the remainder being classified by their UCDAI score as severely relapsing. At the eight-week study endpoint, 63.9% were in remission, leaving 34.0% and 2.1% in mild/moderate and severe relapse, respectively. The median UCDAI score for all evaluable cases was 4 (IQR 1 to 6). Initial exploratory analysis using the whole dataset compared the efficacy of individual item response versus summary UCDAI scores on response prediction of EQ-5D domains. Using UCDAI item responses as predictor variables, the percentage of variability in EQ-5D domain response attributable to each regression variance ranged from 20.4% (anxiety and depression sub-domain) to 42.5% (self-care subdomain). Summary UCDAI score was a less effective predictor of the EQ-5D domains compared with individual UCDAI items, therefore we only report UCDAI individual item scores (pseudo-R 2 = 13.2% and 20.4%, respectively; Table 3 ). Items from the abbreviated-UCDAI (no endoscopy score) showed comparable explanatory performance (pseudo-R 2 range of 21.3% to 38.0%) to full UCDAI scores that included the result of endoscopic examination (Table 3) . Because individual items were better at predicting utility, and the observation that inclusion of endoscopy does not influence patient-rated disease experience measured using the EQ-5D, we constructed models using the abbreviated-UCDAI data because of the increased number of observations that increases statistical power. The parameter estimates for predicting EQ-5D response based individual abbreviated-UCDAI items are shown in Table 4 .
Applying the final model to the PINCE dataset, the mean utility predicted by the abbreviated-UCDAI item algorithm was 0.844 (SD 0.104) and 0.852 (SD 0.175) by estimation directly from EQ-5D responses (p = 0.238 [paired-t test]). The mean squared error (MSE) between the actual and mean predicted utilities was 0.019 (SD 0.037). The mean predicted EQ-5D index was within 0.03 U of the actual utility in 38.1% of cases and within 0.10 U of the actual utility in 58.5% of cases. Good correlation was observed between predicted and actual utility (r = 0.611; p b 0.001).
In the PODIUM dataset, evaluable data were available for 359 patients, 53% of whom were male, and for which the median age at screening was 48 years (IQR 37 to 59). At baseline, all patients were in remission and had an estimated mean EQ-5D index of 0.945 U (SD 0.023). At 12 months, 73.8% of patients remained in remission, 22.6% were in mild/ moderate relapse, and 3.6% were in severe relapse. There were no baseline differences between patients relapsing or remitting at 12 months; however, significant differences in 12-month mean predicted utility emerged. For patients in remission at 12-months, their mean predicted utility was 0.940 U (95% CI 0.937 to 0.943) whilst for mild/moderate relapsing cases mean predicted utility was 0.775 (95% CI 0.751 to 0.800) and 0.660 (95% CI 0.595 to 0.725) for those in severe relapse (p ANOVA b 0.001; Fig. 1 ).
Discussion
In this study we have tested the ability of the UCDAI with or without endoscopy to predict patient perceived HRQoL. The The parameter estimate matrix is applied to suitable data using the Monte Carlo bootstrap simulation method detailed by Gray et al. 17 A copy of the simulation model in Excel spreadsheet format is available from the corresponding author.
near-identical pseudo-R 2 statistic of domain models using either the full UCDAI or abbreviated-UCDAI assessment suggests that endoscopy adds little information to patient perception of UC disease severity as measured using the EQ-5D. These findings are consistent with previous investigations which suggested that endoscopy does not significantly contribute to indices of perceived UC disease activity. 12 One possibility for the observation that endoscopy scores collected as part of the UCDAI do not contribute to patient disease perception using the EQ-5D can be explained by differences in what the two instruments are attempting to measure. Whilst endoscopy is useful for measuring mucosal appearance, this does not necessarily relate to the clinical course of the disease. 20 In all likelihood, the patient experience reported using the EQ-5D is more likely influenced by symptoms that they can perceive. For example, stool frequency and rectal bleeding are more likely to influence the patient perception and likely to influence HRQoL scores. Because clinicians and patients are assessing UC symptoms under a different set of criteria it is possible that in some cases clinical indexes such as the UCDAI and patient HRQoL scores will differ. In fact, in a previous analysis using this same data set, the authors of this study have shown that patient perception of disease had improved at 4 weeks based on the EQ-5D index, whereas clinical symptoms were not found to improve until the eight week follow-up visit using the UCDAI. 21 In recent years considerable interest has focused on trying to establish the most appropriate outcomes to include in UC disease activity indices. The available disease activity instruments include a range of clinical, biomedical, and endoscopic assessments for estimating disease severity. 9, 13 Of the available UC severity indices, none include patientrated disease elements, but recent consensus statements suggest that patient reported quality of life instruments should be included as secondary outcome measures in clinical trials. 9 With respect to the role of endoscopy in clinical trials, evidence suggests that mucosal healing is probably a major endpoint as a predictor of a better outcome and of a lower risk of relapse. 22 However, one still needs to better define it using new consensual criteria adapted to the modern endoscopy material as previous criteria were defined using rigid endoscopy. 23 The results described here will likely add to the existing controversy regarding the role of endoscopy in clinical trials and disease activity instruments.
In this study response mapping of UC severity using the UCDAI to EQ-5D domains produced estimates of preferencebased health-related utility consistent with worsening disease severity in UC (Fig. 1) . Furthermore, we demonstrated that utility could be estimated using this method in subjects where no endoscopic evaluation was made. The estimates of utility derived in this study illustrate the large decrease in the disease state by comparison with remission which can be essentially regarded as a normal state. Patients in mild-to-moderate relapse had health-related utility comparable to those with cardiac dysrhythmia or gout, whilst patients with a severe relapse had similar disutility to those with emphysema or renal failure. 24 These findings should help future investigators conducting a cost-effectiveness analysis in situations where HRQoL was not reported directly in the trial, and where UCDAI scores are available.
The mapping results presented in Fig 1 might also reveal something about differences in disease perception between patients and clinicians. When patients are classified according to the UCDAI as being in remission, the patients report health state utility equivalent to normal healthy persons of around 0.95 units with limited variance around the mean. However, when patients are classified as severe UC, variances in utility scores are much larger. This variance could be explained by differences in disease perception to UC symptoms between study participants. Alternatively, this could be explained by differences in disease perception between patients and clinicians. For example, patients with an inflamed mucosa might be rated as severe according to the UCDAI, however if the inflamed mucosa doesn't manifest itself to the point of disturbing the patient they might still rate themselves as having a good HRQoL. Patients HRQoL can be influenced by a range of factors some of which are related to UC clinical symptoms and others that are not.
This study had limitations that are worth noting. Although we were able to demonstrate comparable utility at a disease severity group level in a separate sample (from the PODIUM study), these statistical models ideally require further external validation with unrelated cohorts. Further refinement would be possible with the inclusion of other patient data such as body mass index and co-morbidity, and the enhanced version of the UCDAI which includes a patient's functional assessment. Recently, other investigators have cautioned against over-optimism about mapping functions and emphasized that they may not be accurate enough for comparisons of individuals. 25 This is particularly true of response mapping, as used here, hence our use of repeated simulation in order to derive mean predicted utility. At the current stage of development we consider these models to be sufficiently reliable to estimate differential utility between classes of UC severity in economic evaluations. The simulation model is available in Excel spreadsheet form to other researchers wishing to estimate the EQ-5D index from UCDAI scores. Furthermore, the pseudo-R 2 statistics of the individual domain models reported here cannot be directly compared with R 2 values obtained from ordinary least square-based transfer to utility models. 26 However, the absolute prediction error of 0.08 U for the PINCE dataset is comparable to the 0.07 figure reported by Franks in the conversion of SF-12 to the EQ-5D index using data from a large US general population survey. 27 The results provided in Table 4 will aid other investigators hoping to derive utility values from UCDAI data collected in various clinical settings.
The possibility also exists that bias could be introduced into our analysis by treating four different observations from the same patient as independent observations in the mapping exercise. Aware of the potential bias this might introduce, the prediction of utility by Monte Carlo bootstrap simulation included a stage where each estimated response probability was compared against a random number to determine whether it was valid as recommended by Gray et al. 17 By using this technique with 250 replications for each observation we are confident that our estimates of EQ-5D utility are stable. Furthermore, based on four observation points and 127 patients recruited it would be expected that there would be 508 observations available from the PINCE study. However, we report here that only 441 data points were available for mapping the UCDAI and EQ-5D. The difference between expected and observed data points is attributed to patient dropout over the course of the study.
To control for potential selection bias we compared baseline demographics between patient dropouts and those that completed the study where no difference was observed for age or gender balance between these two groups.
Unsurprisingly, in this analysis patients with relapsing UC showed considerable decrements in health-related utility consistent with disease severity in excess of minimum clinically important differences. Whilst the EQ-5D index minimal clinically important difference (MCID) has not been unequivocally established, previous research has estimated an MCID of 0.033 to 0.074. The former is based on an effect size of 0.2 in the large Medical Expenditure Panel Survey conducted in the US; the latter is based on changes using the SF-36 as an anchor in 11 different patient populations. 28 For comparison purposes, previous research has found the MCID of other use instruments to be from 0.03 to 0.041 for the SF-6D and 0.03 for the Health Utilities Index. 29 The MCID for EQ-5D scores are important for understanding whether differences in UCDAI disease severity represent clinically significant differences. As reported in this study differences in EQ-5D scores between UCDAI severity scores are greater than 0.074, which is a pessimistic MCID estimate, suggesting that the differences between UCDAI severity scores are clinically important.
In this study we have described health state utility scores for established UC severity categories. We have also shown that health state utility values between the different UC health states represent clinically important differences based on mapped health state utility scores for each UC health state. The utility values reported here will likely aid those conducting health economic studies in UC to define treatment benefits relative to treatment costs in future economic evaluations. Furthermore, we have shown that diagnostic endoscopy scores do not add to the patient experience of their condition based on patient-rated disease severity using the EQ-5D. This finding does not diminish the importance of clinical endoscopy as an important diagnostic tool; rather we illustrate that for clinical trial purposes it does not predict severity ratings derived from the UCDAI severity index.
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